Loading organizations...

§ Private Profile · Novi, MI, USA
SoftVue, a radiation-free 3D whole breast ultrasound tomography system for dense breast cancer screening.
Delphinus Medical Technologies is a Novi, Michigan-based medical device company that develops SoftVue, a 3D whole breast ultrasound tomography system designed for dense breast imaging. The company's technology provides radiation-free imaging without breast compression, scanning the entire breast in a single pass to identify cancers frequently missed by traditional mammography. The enterprise operates with a team of approximately 20 employees and has secured significant capital to commercialize its diagnostic hardware, including an $11 million Series B and a $39 million Series C venture round. In August 2023, the firm raised an additional $12 million in growth capital from Trinity Capital, adding to a capitalization table that features lead investors Arboretum Ventures and Venture Investors. Originating as a spin-out from the Karmanos Cancer Institute and Wayne State University, Delphinus Medical Technologies was founded in 2009 by Neb Duric.
Delphinus Medical Technologies has raised $101.0M across 5 funding rounds.
Delphinus Medical Technologies has raised $101.0M in total across 5 funding rounds.
Delphinus Medical Technologies has raised $101.0M across 5 funding rounds. Most recently, it raised $12.0M Other Equity in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 22, 2023 | $12M Venture Round | Lauren Cosentino | — | Announced |
| Sep 1, 2022 | $30M Series D | — | Beringea, Galen Partners, Paul Mccreadie, Hopen Life Science Ventures, North Coast Technology Investors, Venture Investors, Waycross Ventures | Announced |
| Sep 1, 2015 | $40M Series C | John Neis | Beringea, Galen Partners, Arboretum Ventures, Hopen Life Science Ventures, North Coast Technology Investors, Waycross Ventures | Announced |
| Sep 1, 2013 | $11M Series B | Beringea, Paul Mccreadie | Galen Partners, North Coast Technology Investors | Announced |
| Jul 1, 2010 | $8M Series A | Beringea, Arboretum Ventures | Galen Partners, North Coast Technology Investors | Announced |
Delphinus Medical Technologies has raised $101.0M in total across 5 funding rounds.
Delphinus Medical Technologies's investors include Lauren Cosentino, Beringea, Galen Partners, Paul McCreadie, Hopen Life Science Ventures, North Coast Technology Investors, Venture Investors, Waycross Ventures, John Neis, Arboretum Ventures.
Delphinus Medical Technologies is a medical‑device company that develops and commercializes SoftVue, a 3D whole‑breast ultrasound tomography system designed to improve breast cancer detection—particularly in women with dense breasts—by delivering radiation‑free, compression‑free imaging of the entire breast in a single scan[1][3].
High‑Level Overview
For the product/company:
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick reiteration: Delphinus Medical Technologies is best understood today as the developer and commercializer of SoftVue, a patented 3D whole‑breast ultrasound tomography system focused on improving detection in women with dense breasts while avoiding radiation and compression[1][3].